Aldosterone is not Involved in the Ventricular Remodeling Process Induced by Tobacco Smoke Exposure

Priscila P. dos Santos a, Bruna F. Nogueira a, Bruna P. M. Rafacho a, Paula S. Azevedo a, Bertha F. Polegato a, Fernanda Chiuso-Minicucci b, Camila Bonomo a, Meliza G. Roscani a, Sofia F.G. Zorzella-Pezavento b, Suzana E. Tanni a, Elenize J. Pereira a, Marina P. Okoshi a, Sergio A. R. Paiva a, Leonardo A. M. Zornoff a, Marcos F. Minicucci a

a Internal Medicine Department, Botucatu Medical School, Univ Estadual Paulista (UNESP), Botucatu; b Department of Microbiology and Immunology, Institute of Biosciences, Sao Paulo State University, Botucatu

Key Words
GLUT4 • Inflammation • Ventricular remodeling • Cigarette smoke

Abstract
Background/Aims: Renin-angiotensin-aldosterone system blockade with a mineralocorticoid-receptor antagonist has not yet been studied in exposure to tobacco smoke (TS) models. Thus, this study investigated the role of spironolactone on cardiac remodeling induced by exposure to tobacco smoke. Methods: Male Wistar rats were divided into 4 groups: a control group (group C, n=11); a group with 2 months of cigarette smoke exposure (group TS-C, n=13); a group that received spironolactone 20 mg/kg of diet/day and no cigarette smoke exposure (group TS-S, n=13); and a group with 2 months of cigarette smoke exposure and spironolactone supplementation (group S, n=12). The rats were observed for a period of 60 days, during which morphological, biochemical and functional analyses were performed. Results: There was no difference in invasive mean arterial pressure among the groups. There were no interactions between tobacco smoke exposure and spironolactone in the morphological and functional analysis. However, in the echocardiographic analysis, the TS groups had left chamber enlargement, higher left ventricular mass index and higher isovolumetric relaxation time corrected by heart rate compared with the non-TS groups. In vitro left ventricular diastolic function also worsened in the TS groups and was not influenced by spironolactone. In addition, there were no differences in myocardial levels of IFN-γ, TNF-α, IL-10, ICAM-1 and GLUT4 [TS: OR 0.52, 95%CI (-0.007; 0.11); Spironolactone: OR -0.01, 95%CI (-0.07;0.05)]. Conclusion: Our data do not support the participation of aldosterone in the ventricular remodeling process induced by exposed to cigarette smoke.
Introduction

Exposure to tobacco smoke is currently the leading cause of preventable death. Approximately 440,000 deaths occur annually in the United States due to smoking [1, 2]. In addition to the well-known vascular effects of tobacco, some studies have suggested that this exposure may induce ventricular remodeling [3-10]. Tobacco smoke exposure results in left ventricular enlargement and hypertrophy and systolic and diastolic dysfunction evaluated by in vivo and in vitro techniques [3-10]. The mechanisms involved in this remodeling process are not completely known. Potential mechanisms for these alterations include inflammation [8, 11], oxidative stress [8, 11], metalloproteinase [5] and mitogen-activated protein kinase activation [6], and hemodynamic and neurohormonal changes, such as renin-angiotensin-aldosterone system (RAAS) activation [12].

RAAS blockade has already been studied in cardiac remodeling induced by tobacco smoke. Duarte et al. showed that lisinopril, an angiotensin converting enzyme inhibitor, attenuated left ventricle enlargement, myocyte hypertrophy and systolic dysfunction due to tobacco smoke exposure. In addition, these alterations were not associated with connexin 43 distribution, cytokine production or collagen content [12]. However, RAAS blockade with a mineralocorticoid-receptor antagonist, such as spironolactone, has not yet been studied in tobacco smoke exposure models.

Mineralocorticoid-receptor antagonists have been used in different models of cardiac remodeling. The American Heart Association recommends their use for patients with systolic dysfunction and NYHA heart failure classes III and IV, and for systolic dysfunction after myocardial infarction [13]. Recently, the EMPHASIS-HF study showed that eplerenone reduced hospital admission and cardiovascular and all-cause mortality in patients with heart failure and mild symptoms [14]. Accordingly, the 2011 guideline updates have recommended eplerenone or spironolactone for systolic heart failure patients with NYHA class II symptoms [15, 16].

The potential effects of aldosterone blockers are reduced inflammation, decreased collagen amount and attenuated myocyte hypertrophy [17, 18]. In addition, spironolactone can also influence glucose transport. Lastra et al. showed that low-dose spironolactone improves insulin-stimulated glucose transport in the skeletal muscle of transgenic rats with increased tissue renin-angiotensin system activity [19]. In this study, spironolactone increased expression of insulin receptor substrate and glucose transporter type 4 (GLUT4) [19].

Thus, this study investigated the role of spironolactone on cardiac remodeling induced by tobacco smoke exposure.

Materials and Methods

All experiments and procedures were performed in accordance with the National Institutes of Health’s Guide for the Care and Use of Laboratory Animals and were approved by the Animal Ethics Committee of our institution.

Male Wistar rats that weighed 200-230 g were assigned to 4 experimental groups: a control group (group C, n=11); a group with 2 months of cigarette smoke exposure (group TS-C, n=13); a group that received spironolactone 20 mg/kg of diet/day and no cigarette smoke exposure (group TS-S, n=13); and a group with 2 months of cigarette smoke exposure and spironolactone supplementation (group S, n=12). The amount of food given was determined by the amount ingested by the exposure to tobacco smoke groups. Water was supplied ad libitum. The rats were observed for 60 days, during which morphological, biochemical and functional analyses were performed. The TS rats were exposed to cigarette smoke in a chamber (95x80x65 cm) that was connected to a smoking device based on a model published by Wang et al. [20] and adapted by Paiva et al. [21]. The smoke was drawn out of filtered commercial cigarettes (composition per unit: 1.1 mg nicotine, 14 mg tar and 15 mg carbon monoxide) with a vacuum pump and exhausted into the smoking chamber. During the first week, the number of cigarettes was gradually increased from 5 to 10 cigarettes
over a 30 min period, administered twice each afternoon. Subsequently, 10 cigarettes were used for each exposure, and the rats were exposed to the smoke four times/day: twice in the morning and twice in the afternoon. Thus, the TS groups smoked 40 cigarettes/day. Considering the carboxyhemoglobin levels, this protocol is similar to 3–4 pack/day in human.

Invasive blood pressure measurement
After the observation period, invasive blood pressure measurement was performed. The rats were lightly anesthetized with an intramuscular (IM) injection of ketamine (50 mg/kg) and xylazine (1 mg/kg). An arterial catheter was placed in the left femoral artery to measure the mean arterial pressure (5 rats per group).

Echocardiographic analysis
After 2 months of exposure, all of the animals were weighed and evaluated by transthoracic echocardiography. The exams were performed using a commercially available echocardiograph (SONOS 2000, Hewlett-Packard Medical Systems, Andover, MA) that was equipped with a 7.5-MHz, phased-array transducer. The imaging was performed with a 60° sector angle and a 3-cm imaging depth. The rats were lightly anesthetized with an intramuscular (IM) injection of ketamine (50 mg/kg) and xylazine (1 mg/kg). The rats’ chests were shaved, and the rats were placed in a left lateral position. Targeted 2-D, M-mode echocardiograms were obtained from short-axis views of the left ventricle (LV) at or just below the tip of the mitral-valve leaflet TS and at the level of the aortic valve and left atrium. M-mode images of the LV, left atrium and aorta were recorded on a black-and-white thermal printer (Sony Up-890MD) at a sweep speed of 100 mm/s. All of the tracings were manually measured with calipers by the same observer using the leading-edge method recommended by the American Society of Echocardiography [22]. The data represent the mean of measurements from at least five consecutive cardiac cycles. The LV end-diastolic dimension (LVDD) and posterior wall thickness (LVWT) were measured at the maximal diastolic dimension, whereas the end-systolic dimension (LVSD) was measured at the maximal anterior motion of the posterior wall. The left atrium was measured at its maximal diameter, and the aorta was measured at the end of diastole. LV systolic function was assessed by calculating the fractional shortening \( [(LVDD - LVSD)/LVDD \times 100] \) and the ejection fraction \( [(LVDD^3 - LVSD^3)/LVDD^3] \). The transmitral diastolic flow (E and A) velocities were obtained from the apical four-chamber view. The E/A ratio was used as an index of LV diastolic function.

In vitro left ventricular function analysis
The procedures and measurements were performed following a previously described method [23]. One day after the echocardiographic study, the rats were anesthetized with thiopental sodium (50 mg/kg, i.p.) and given heparin (2000 IU, i.p.). The chest was opened by median sternotomy under artificial ventilation. The entire heart was quickly removed and transferred to a perfusion apparatus (model 830 Hugo Sachs Eletronick-Green-strasse). The ascending aorta was isolated and cannulated for retrograde perfusion with filtered and oxygenated Krebs-Henseleit solution (115mM NaCl, 5.4 mM KCl, 2.5 mM CaCl\(_2\), 1.2 mM MgSO\(_4\), 1.15 mM NaH\(_2\)PO\(_4\), 1.2 mM Na\(_2\)PO\(_4\), 25 mM NaHCO\(_3\), and 11 mM glucose) which was maintained at a constant temperature and perfusion pressure (37°C and 75 mmHg). The main pulmonary artery was cut to vent the right ventricle and a latex balloon was placed into the left ventricle via the mitral valve orifice. The proximal end of the balloon previously attached to a plastic cannula was connected to a three-way stopcock that permitted filling the balloon with saline and emptying it. The ventricular pressure was measured with a 23XL transducer and a WindoGraph® recorder (Gould Inc., Valley View, OH, USA). In the isovolumetrically beating ventricle, paced at 240 beats/min with an artificial pacer; model 79232 (Hugo Sachs Eletronick), the balloon volume was increased in 0.02 ml increments over a diastolic range of 0-25 mmHg. The pressure and volume within the balloon were recorded following each increment and corresponded to the left ventricular pressure and volume respectively. After pressure recordings, the hearts were removed from the perfusion apparatus, and left ventricles were weighed.

Morphometric analysis
At the completion of the functional analyses, the left and right ventricles, including the interventricular septum, were dissected, separated and weighed. Transverse sections of the LV were fixed in 10% buffered formalin and embedded in paraffin. Five-micron-thick sections were stained with hematoxylin and eosin.
(HE) or the collagen-specific stain, picrosirius red (Sirius red F3BA in aqueous-saturated picric acid). The myocyte cross-sectional area was determined for a minimum of 100 myocytes per HE-stained cross section. The measurements were obtained from digital images (400× magnification) that were collected with a video camera attached to a Leica microscope; the images were analyzed with Image-Pro Plus 3.0 software (Media Cybernetics; Silver Spring, MD). The myocyte cross-sectional area was measured with a digital pad, and the selected cells were transversely cut so that the nucleus was in the center of the myocyte [21]. The interstitial collagen volume fraction was determined for the entire cardiac section that was stained with Picrosirius Red by analyzing the digital images captured under polarized light (200× magnification). The myocardial tissue components were identified according to the following staining patterns: red for collagen fibers, yellow for myocytes and white for interstitium. The collagen volume fraction was calculated as the sum of all of the connective tissue areas divided by the sum of all of the connective tissue and myocyte areas. On average, 35 microscopic fields were analyzed per heart with a 20× lens. Perivascular collagen was excluded from this analysis [21].

**Western blot analysis**

An antibody against GLUT4 [GLUT 4 mouse monoclonal IgG1 (IF8, sc-53566, dilution 1:500, Santa Cruz Biotechnology)] was used. Briefly, frozen LV isolated from the C (n=6), S (n=6), TS-C (n=7), and TS-S groups (n=7) were homogenized in a buffer containing 50 mmol/L potassium phosphate (pH=7.0), 0.3 mol/L sucrose, 0.5 mmol/L DTT, 1 mmol/L EDTA (pH=8), 0.3 mmol/L PMSF, 10 mmol/L NaF, and phosphatase inhibitor cocktail (1:100; Sigma-Aldrich). The homogenate was centrifuged at 4°C for 20 min at 12,000 ×g. The supernatant was collected, and the total protein content was determined by the Bradford method. These homogenates were also used for cytokine and adhesion molecule analyses.

The samples were subjected to SDS-PAGE electrophoresis. After this procedure, the proteins were electro-transferred to nitrocellulose membranes. Equal loading of the samples (50 μg) and even transfer efficiency were monitored through the use of 0.5% Ponceau S staining of the blotted membrane. The blotted membrane was then blocked (5% nonfat dry milk; 10 mM Tris-HCl, pH=7.6; 150 mM NaCl; and 0.1% Tween 20) for 2 hours at room temperature and incubated with specific antibodies overnight at 4°C. Binding of the primary antibody was detected by a peroxidase-conjugated secondary antibody (mouse, 1:10,000, for 1.5 h at room temperature) and developed by enhanced chemiluminescence (Amersham Biosciences) detected by autoradiography. Quantification analysis of the blots was performed using Scion Image software (based on NIH Image). The targeted bands were normalized to GAPDH.

**Evaluation of myocardial cytokine and intercellular adhesion molecule 1 (ICAM-1) concentrations**

Myocardial cytokine production was measured by ELISA according to the manufacturer’s instructions (R&D Systems), as previously described [24, 25]. Briefly, cardiac homogenate were coated with capture antibodies for IFN-γ, TNF-α, IL-10, and ICAM-1 in 96-well plates (Nunc). Plates were incubated overnight and then blocked during 2 h with 1% albumin in PBS. Standard rat cytokines were added and the plates incubated during 2 h. Biotinylated anti-IFN-γ, anti-TNF-α, anti-IL-10, and anti-ICAM were added and the plates were incubated for an additional 2 h at room temperature. Plates were incubated at room temperature for 30 min with streptavidin and then revealed by adding H₂O₂ + OPD (Sigma). Color development was stopped with H₂SO₄ and optical density was measured at 492 nm.

**Statistical analysis**

The data are expressed as the mean ± SD and regression coefficients and 95% confidence interval. To explore the interactions between tobacco smoke exposure and spironolactone, we performed multiple linear regression analyses with robust standard errors. The robust regression analysis provided an alternative to a least squares regression model when the fundamental assumptions were unfulfilled by the nature of the data and data transformation was not possible. We did not perform a two-way ANOVA analysis, because we could not normalize our data. The associations are expressed by the regression coefficients and 95% confidence interval of the regression coefficients. A p value of less than 0.05 denotes the presence of a significant difference. Data analysis was performed with STATA® 10.0 - Corp (College Station, Texas, USA).
Results

The echocardiographic data are listed in Tables 1 and 2. There were no interactions between tobacco smoke exposure and spironolactone. However, the TS groups showed left chamber enlargement and a higher left ventricular mass index compared with the non-TS...
In addition to these morphological changes, tobacco smoke exposure led to a higher isovolumetric relaxation time corrected by heart rate. In accord with the echocardiography analysis, in vitro left ventricular diastolic function worsened in the TS groups and was not influenced by spironolactone administration (Table 3).

Table 3. In vitro left ventricular function data. C: control animals; S: spironolactone animals; TS: animals exposed to tobacco smoke; +dp/dt max: maximum rate of ventricular pressure rise; -dp/dt max: decreased maximum rate of ventricular pressure rise; MAP: mean arterial pressure. Panel A: data are expressed as the mean ± SD. Panel B: associations are expressed by regression coefficients and 95% confidence interval of the regression coefficients. * p<0.05

Table 4. Morphological data. C: control animals; S: spironolactone animals; TS: animals exposed to tobacco smoke; BW: body weight; LVW: left ventricular weight; RVW: right ventricular weight; RVWC: right ventricular water content; WC: water content; IC: interstitial collagen volume fraction; CSA: cross-sectional area. Panel A: data are expressed as the mean ± SD. Panel B: associations are expressed by regression coefficients and 95% confidence interval of the regression coefficients. * p<0.05.
Regardless of the potential effects of tobacco and spironolactone on arterial pressure, there was no difference in invasive mean arterial pressure among the groups (Table 3).

The morphological data are listed in Table 4. The BW-corrected left ventricular weight (LVW) and BW-corrected right ventricular weight (RVW) were elevated in the TS group. In addition, the TS group had a larger myocyte cross-sectional area (CSA). Tobacco smoke exposure also increased the lung and liver water content. There were no interactions between TS and spironolactone in these morphometric variables. The interstitial collagen volume fraction was similar among the groups (Table 4).

Furthermore, TS and spironolactone administration did not affect myocardial levels of IFN-γ, TNF-α, IL-10 and ICAM-1. Although the difference was not statistically significant, spironolactone reduced myocardial IL-10 and ICAM-1 despite tobacco smoke exposure (Table 5).

There was also no difference in GLUT4 expression among the groups (Table 5).

**Discussion**

Our study showed that tobacco smoke exposure induces morphological alterations and diastolic dysfunction in rats. In addition, these alterations were not related to inflammation or ICAM-1 or GLUT4 expression. Importantly, spironolactone does not influence ventricular remodeling induced by tobacco smoke exposure.

Consistent with previous reports, our data indicate that tobacco smoke exposure induces ventricular remodeling [3-10]. Currently, ventricular remodeling is defined as genome expression resulting in molecular, cellular and interstitial changes and manifested clinically as changes in the size, shape and function of the heart [26]. Although it can initially be a compensatory process, chronic ventricular remodeling leads to progressive ventricular dysfunction and sudden death [26].
One of the potential effects of aldosterone blockers is the inhibition of myocyte hypertrophy. Aldosterone stimulates hypertrophy by mechanical effects due to volume overload and direct effects due to myocyte growth. Okoshi et al. showed in serum-free culture of neonatal rat ventricular myocytes that aldosterone-induced hypertrophy was followed by increased mRNA levels of atrial natriuretic peptide and alpha- and beta-myosin heavy chains [17]. In addition, these alterations were attenuated by spironolactone [17]. Despite this potential effect, in this study, ventricular hypertrophy induced by tobacco smoke was not attenuated by spironolactone.

Spironolactone may also modulate the inflammatory process mediated by aldosterone. In other models of heart failure, increased production of cytokines, such as IFN-γ and TNF-α, was associated with hypertrophy, fibrosis and left ventricular dysfunction [27, 28]. Interestingly, tobacco smoke did not increase myocardial inflammatory cytokines in our study. Although we have already observed these cytokine patterns in previous studies, ICAM-1 expression has not yet been evaluated in tobacco exposure models [8, 11]. Importantly, the expression of adhesion molecules is essential for the influx of inflammatory cells into the myocardium. In addition, previous reports have shown that ICAM-1 expression increases after myocardial infarction [29]. However, in this study, myocardial ICAM-1 did not increase after tobacco smoke exposure. Surprisingly, although the difference was not statistically significant, spironolactone administration reduced myocardial concentrations of IL-10 and ICAM-1, despite tobacco smoke exposure.

The influence of tobacco exposure and spironolactone administration on insulin resistance was also evaluated. Smoking is a well-known risk factor for insulin resistance. However, the mechanisms responsible for smoking-induced insulin resistance are unclear. Tatebe and Morita showed in C2C12 skeletal myocytes that in the presence of palmitate, nicotine enhanced TNF-α expression, suppressed GLUT4 translocation to the plasma membrane and impaired glucose uptake into cells [30]. Rincón et al. also showed that insulin-stimulated glucose transport is impaired in human skeletal muscle in smokers [31]. However, in this clinical study, the altered glucose uptake was not explained by altered GLUT4 protein expression but was related to increased serum free fatty acids and triglyceride levels [31].

Spironolactone can also influence insulin resistance. Human studies have shown an association between increased plasma levels of aldosterone and insulin resistance in patients with metabolic syndrome and primary aldosteronism [32, 33]. Some authors have suggested that this alteration is due to the pro-inflammatory effects of aldosterone [19]. In addition, Lastra et al. showed that spironolactone improves insulin-stimulated glucose transport and GLUT4 expression in the skeletal muscle of transgenic rats with increased RAAS activity [19]. In our study, left ventricular GLUT4 expression was not influenced by tobacco smoke exposure or spironolactone.

Finally, the mechanisms involved in ventricular remodeling induced by tobacco smoke exposure are not fully established. As discussed, MMPs have been implicated in cardiac remodeling. In fact, when rats with volume overload were exposed to tobacco smoke, there was increased expression of MMP-9 and TIMP-1 [34]. Another study demonstrated that trimetazidine protects against smoking-induced left ventricular remodeling via attenuating oxidative stress, apoptosis, and inflammation [35]. In addition, neurohormonal blockade is an interesting target for attenuating cardiac remodeling in this scenario. Indeed, administration of propranolol attenuated some of the variables of ventricular remodeling induced by smoking in rats [36]. In addition, a recent study conducted in our laboratory showed that lisinopril attenuated left ventricle enlargement, myocyte hypertrophy and systolic dysfunction due to tobacco smoke exposure [12]. However, in this study, spironolactone did not influence ventricular remodeling. Therefore, our data suggested that, differently of renin-angiotensin and adrenergic systems, aldosterone is not involved in ventricular remodeling induced by smoking.

In conclusion, our data do not support the participation of aldosterone in the ventricular remodeling process induced by exposed to cigarette smoke.
Conflict of Interest

No conflict of interest declared.

Acknowledgements

This study was funded by the "Fundação de Amparo à Pesquisa do Estado de São Paulo" FAPESP (10/10187-2) and "Conselho Nacional de Desenvolvimento Científico e Tecnológico" CNPq (473091/2010-0).

Reference


22 Lang RM, Bierig M, Devereaux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward JB, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ, Chamber Quantification Writing Group; American Society of Echocardiography’s Guidelines and Standards Committee, European Association of Echocardiography: Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-1463.


